Amgen gets fast U.S. FDA review for adding heart benefits to cholesterol drug label

July 27 (Reuters) - Amgen Inc said on Thursday the U.S. Food and Drug Administration granted priority review to the company's request to add important heart safety data to the label of its expensive injectable cholesterol drug Repatha.